SG11201608848XA - Use of ctla4 compound for achieving drug-free remission in subjects with early ra - Google Patents
Use of ctla4 compound for achieving drug-free remission in subjects with early raInfo
- Publication number
- SG11201608848XA SG11201608848XA SG11201608848XA SG11201608848XA SG11201608848XA SG 11201608848X A SG11201608848X A SG 11201608848XA SG 11201608848X A SG11201608848X A SG 11201608848XA SG 11201608848X A SG11201608848X A SG 11201608848XA SG 11201608848X A SG11201608848X A SG 11201608848XA
- Authority
- SG
- Singapore
- Prior art keywords
- subjects
- early
- free remission
- achieving drug
- ctla4 compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1777—Integrin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461984287P | 2014-04-25 | 2014-04-25 | |
PCT/US2015/027281 WO2015164595A1 (en) | 2014-04-25 | 2015-04-23 | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201608848XA true SG11201608848XA (en) | 2016-11-29 |
Family
ID=53055123
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201608848XA SG11201608848XA (en) | 2014-04-25 | 2015-04-23 | Use of ctla4 compound for achieving drug-free remission in subjects with early ra |
Country Status (13)
Country | Link |
---|---|
US (2) | US20170042972A1 (en) |
EP (1) | EP3134109A1 (en) |
JP (1) | JP2017513903A (en) |
KR (1) | KR20160145789A (en) |
CN (1) | CN106456712A (en) |
AU (1) | AU2015249656A1 (en) |
BR (1) | BR112016023450A2 (en) |
CA (1) | CA2947217A1 (en) |
EA (1) | EA201692126A1 (en) |
IL (1) | IL248421A0 (en) |
MX (1) | MX2016013611A (en) |
SG (1) | SG11201608848XA (en) |
WO (1) | WO2015164595A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41459A (en) | 2015-02-03 | 2017-12-12 | Als Therapy Development Inst | ANTI-CD40L ANTIBODIES AND METHODS FOR TREATING CD40L ILLNESSES OR DISORDERS |
RS61943B1 (en) | 2015-04-17 | 2021-07-30 | Alpine Immune Sciences Inc | Immunomodulatory proteins with tunable affinities |
GB2578037A (en) | 2017-05-24 | 2020-04-15 | Als Therapy Development Inst | Therapeutic anti-CD40 ligand antibodies |
EP4219540A3 (en) | 2017-10-10 | 2023-12-06 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
US20200283500A1 (en) | 2017-10-18 | 2020-09-10 | Alpine Immune Sciences, Inc. | Variant icos ligand immunomodulatory proteins and related compositions and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
DK1372696T3 (en) * | 2000-07-03 | 2008-11-03 | Bristol Myers Squibb Co | Methods for treating rheumatic diseases using a soluble CTLA4 molecule |
PL377603A1 (en) | 2002-12-23 | 2006-02-06 | Bristol-Myers Squibb Company | Product quality enhancement in mammalian cell culture processes for protein production |
EP1575998A4 (en) | 2002-12-23 | 2007-07-25 | Bristol Myers Squibb Co | Mammalian cell culture processes for protein production |
CN106589132B (en) | 2005-12-20 | 2022-03-29 | 布里斯托尔-迈尔斯斯奎布公司 | Composition and method for producing a composition |
EP1962886B2 (en) | 2005-12-20 | 2022-02-23 | Bristol-Myers Squibb Company | Stable protein formulations |
US7915222B2 (en) * | 2008-05-05 | 2011-03-29 | Bristol-Myers Squibb Company | Method of preventing the development of rheumatoid arthritis in subjects with undifferentiated arthritis |
-
2015
- 2015-04-23 WO PCT/US2015/027281 patent/WO2015164595A1/en active Application Filing
- 2015-04-23 CN CN201580021896.4A patent/CN106456712A/en active Pending
- 2015-04-23 KR KR1020167032495A patent/KR20160145789A/en active Search and Examination
- 2015-04-23 EP EP15721091.5A patent/EP3134109A1/en not_active Withdrawn
- 2015-04-23 SG SG11201608848XA patent/SG11201608848XA/en unknown
- 2015-04-23 CA CA2947217A patent/CA2947217A1/en not_active Abandoned
- 2015-04-23 JP JP2016564163A patent/JP2017513903A/en active Pending
- 2015-04-23 US US15/306,198 patent/US20170042972A1/en not_active Abandoned
- 2015-04-23 MX MX2016013611A patent/MX2016013611A/en unknown
- 2015-04-23 BR BR112016023450A patent/BR112016023450A2/en not_active Application Discontinuation
- 2015-04-23 AU AU2015249656A patent/AU2015249656A1/en not_active Abandoned
- 2015-04-23 EA EA201692126A patent/EA201692126A1/en unknown
-
2016
- 2016-10-20 IL IL248421A patent/IL248421A0/en unknown
-
2019
- 2019-10-29 US US16/666,572 patent/US20200069772A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2016013611A (en) | 2017-02-02 |
US20170042972A1 (en) | 2017-02-16 |
IL248421A0 (en) | 2016-11-30 |
WO2015164595A1 (en) | 2015-10-29 |
EP3134109A1 (en) | 2017-03-01 |
KR20160145789A (en) | 2016-12-20 |
JP2017513903A (en) | 2017-06-01 |
EA201692126A1 (en) | 2017-03-31 |
AU2015249656A1 (en) | 2016-11-03 |
BR112016023450A2 (en) | 2017-10-17 |
CN106456712A (en) | 2017-02-22 |
CA2947217A1 (en) | 2015-10-29 |
US20200069772A1 (en) | 2020-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1244000B (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
HRP20182134T1 (en) | Triazine compound and use thereof for medical purposes | |
GB201403093D0 (en) | Therapeutic compounds and their use | |
IL248767B (en) | Trimethoxyphenyl-benzimidazole compound for use in the treatment of cancer | |
IL251905A0 (en) | Apilimod for use in the treatment of renal cancer | |
IL283335B (en) | Dihydropyrimidin-2-one compounds and medical use thereof | |
IL248421A0 (en) | Use of ctla4 compound for achieving drug-free remission in subjects with early ra | |
HK1243055A1 (en) | Compounds for use in anthelminthic treatment | |
GB201413357D0 (en) | Antibodies for treatment and diagnosis | |
IL251903B (en) | Apilimod for use in the treatment of colorectal cancer | |
IL250507B (en) | Anti-ck8 antibodies for use in the treatment of cancers | |
SG11201701076TA (en) | Diagnosis of cancer | |
ZA201701426B (en) | Compounds for use in anthelminthic treatment | |
ZA201701492B (en) | Pyrazolothiazole compound and medicine | |
GB201403115D0 (en) | Red blood cell detection | |
GB201616880D0 (en) | Compound for use in medicine | |
IL248782A0 (en) | Treatment regimen tiacumicin compound | |
GB201418541D0 (en) | Materials for use with general hyperthermia treatment | |
GB201410118D0 (en) | Early diagnosis of leptospire | |
GB201408233D0 (en) | Use of polyanionic composition | |
GB201401806D0 (en) | Novel methods for diagnosis and therapy | |
ZA201404780B (en) | Composition for use in treatment of diabetes | |
GB201410387D0 (en) | Compounds and their therapeutic use | |
GB201403496D0 (en) | Compounds and their therapeutic use |